Hennion & Walsh Asset Management Inc. grew its position in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 8.6% during the 4th ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...

Nippon Shinyaku will pay Regenxbio $110 million upfront for U.S. and Asia rights to treatments for Hunter and Hurler ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00.Stay ...

Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...

REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double- ...

K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

Rockville’s RegenxBio Inc. (NASDAQ: RGNX) has inked an agreement with a Japanese drug company to get two of its treatment candidates to market — a deal that could be worth $810 million over time.